Can a mango-flavored pill kill intestinal worms?

A new tablet being developed to treat intestinal worms has shown promising results in trials and could help eradicate the parasitic infection that affects around 1.5 billion people worldwide, researchers say.

The mango-flavored pill is a combination of two anti-parasitic drugs that, when used together, appear to be more effective at getting rid of worms.

These worms are caught by contact with food or water contaminated with soil contaminated with worm eggs and infections cause severe gastrointestinal symptoms, malnutrition and anemia.

Researchers say the pill could help overcome future drug resistance problems and better manage the disease on a large scale.

Parasites, also known as soil-transmitted helminths (STHs), are roundworms and hookworms and are endemic in many developing countries with poor hygiene.

Many of those affected are children and there is no preventative treatment other than better sanitation.

According to a study called “LIVING”.Published in the Lancet journal, this new pill could help affected countries achieve their goals World Health Organization to get rid of diseases

It would be taken as a fixed dose of a single pill or three pills on consecutive days.

According to researchers from eight institutions in Europe and Africa, it would be an easy way to cure large numbers of people in mass treatment programs.

“It is easy to administer, because it is only one pill,” says Jose Muñoz, the head of the project.

“Also, we hope to reduce the risk of parasites becoming resistant to drugs by combining two drugs with different mechanisms of action,” says Professor Muñoz.

Once a person is infected, the parasites take root in the person’s digestive tract.

Although the drug albendazole is good for treating some species of STH, it appears to be less effective against others.

In a clinical trial with 1,001 children aged 5-18 in Ethiopia, Kenya and Mozambique, it was found to be more effective in more types of infections when combined with the drug ivermectin.

However, the researchers said the results were inconclusive about how the threadworm was treated.

Professor Hany Elsheikha, an expert in parasitology at the University of Nottingham, said the pill could be a “significant improvement over other treatments” and could be used against multiple parasites.

“There are some challenges with existing medications … so this could be an important addition.”

However, although the study is “promising”, he said it has “some gaps”.

“We don’t know if the results will be the same for adults, for adults, for young children, for those in other parts of the world.”

The results of the trial have been submitted to European and African regulators, and decisions are expected in early 2025.

Participants are now being recruited for another trial involving 20,000 people in Kenya and Ghana.

Dr Stella Kepha, a researcher at the Kenya Medical Research Institute who worked on the study, said the pill had “huge potential to improve the health of affected communities” but there was still “work to be done” to scale up the treatment.